Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis.
Shelby SydnorSwarnendu ChatterjeePhilip CooneySimarjeet KaurThomas MacmillanDaisy StewartIsobel MunroCátia BandeirasAbby PaineFederico FelizziPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Brolucizumab 6 mg Q12W/Q8W was comparable or superior to aflibercept 2 mg and ranibizumab 0.5 mg regimens for various visual and anatomical efficacy outcomes and discontinuation rates.